Natural history

Billions of cicadas are about to emerge from underground in a rare double-brood convergence

Retrieved on: 
Thursday, April 18, 2024

From late April through June 2024, the largest brood of 13-year cicadas, known as Brood XIX, will co-emerge with a midwestern brood of 17-year cicadas, Brood XIII.

Key Points: 
  • From late April through June 2024, the largest brood of 13-year cicadas, known as Brood XIX, will co-emerge with a midwestern brood of 17-year cicadas, Brood XIII.
  • A co-emergence like this of two specific broods with different life cycles happens only once every 221 years.
  • For about four weeks, scattered wooded and suburban areas will ring with cicadas’ distinctive whistling, buzzing and chirping mating calls.
  • Once the eggs hatch, new cicada nymphs will fall from the trees and burrow back underground, starting the cycle again.
  • It’s no accident that the scientific name for periodical 13- and 17-year cicadas is Magicicada, shortened from “magic cicada.”

Ancient visitors

  • Molecular analysis has shown that about 4 million years ago, the ancestor of the current Magicicada species split into two lineages.
  • The resulting three lineages are the basis of the modern periodical cicada species groups, Decim, Cassini and Decula.
  • The sudden appearance of so many insects reminded them of biblical plagues of locusts, which are a type of grasshopper.
  • During the 19th century, notable entomologists such as Benjamin Walsh, C.V. Riley and Charles Marlatt worked out the astonishing biology of periodical cicadas.

Acting in unison

  • This increases their chances of accomplishing their key mission aboveground: finding mates.
  • While periodical cicadas largely come out on schedule every 17 or 13 years, often a small group emerges four years early or late.
  • Early-emerging cicadas may be faster-growing individuals that had access to abundant food, and the laggards may be individuals that subsisted with less.

Will climate change shift Magicicada clocks?

  • As glaciers retreated from what is now the U.S. some 10,000 to 20,000 years ago, periodical cicadas filled eastern forests.
  • Today there are 12 broods of 17-year periodical cicadas in northeastern deciduous forests, where trees drop leaves in winter.
  • Because periodical cicadas are sensitive to climate, the patterns of their broods and species reflect climatic shifts.
  • Although periodical cicadas prefer forest edges and thrive in suburban areas, they cannot survive deforestation or reproduce successfully in areas without trees.
  • In the late 19th century, one Brood (XXI) disappeared from north Florida and Georgia.
  • Climate change could also have farther-reaching effects.
  • As the U.S. climate warms, longer growing seasons may provide a larger food supply.
  • This may eventually change more 17-year cicadas into 13-year cicadas, just as past warming altered Magicicada neotredecim.
  • We hypothesize that this was due to climate warming.


John Cooley receives funding from the National Science Foundation and the National Geographic Society. Chris Simon has received funding from the National Science Foundation, the Fulbright Foundation, the National Geographic Society and the New Zealand Marsden Fund.

Fossil beetles found in a Botswana diamond mine help us to reconstruct the distant past

Retrieved on: 
Wednesday, April 10, 2024

One of the few Cretaceous age deposits that’s been discovered in Africa is at Botswana’s Orapa Diamond Mine.

Key Points: 
  • One of the few Cretaceous age deposits that’s been discovered in Africa is at Botswana’s Orapa Diamond Mine.
  • Recently a team I lead discovered two new species of rove beetles preserved in the sediments of the Orapa Diamond Mine.
  • Rove beetles are typically identified by their unique short elytra (protective wing cases) which expose the rest of the abdomen.
  • Our finds are the first fossil rove beetles ever discovered on the continent and in the southern hemisphere.
  • The fossils closely resemble today’s rove beetles, showing how successful they’ve been in adapting to various environments without significant changes to their bodies.

Identifying the fossils

  • We found the fossils in lacustrine sediments (deposits that accumulate in lake environments).
  • Afristenus orapensis belongs to the stenine rove beetle subgroup while Paleothius mckayi belongs to the subgroup staphylinine.
  • The stenine rove beetle was previously described in Russia, France and Myanmar while the staphylinine rove beetle was previously described in Russia, China, Myanmar and England.
  • So we scoured research articles about fossils of a similar age that have already been studied elsewhere for comparative purposes.

More to find

  • We are currently studying each specimen and preparing academic manuscripts that describe what we’ve found.
  • My hope is that more money will be invested in training more palaeoentomologists in South Africa and on the continent more broadly.
  • The study of fossil insects and plants is an important way to preserve our beloved continent’s heritage.


Sandiso Mnguni receives funding from GENUS (Centre of Excellence in Palaeosciences - UID 86073). He is affiliated with the Sophumelela Youth Development Programme (SYDP).

Bruce Pascoe’s Black Duck is a ‘healing and necessary’ account of a year on his farm, following a difficult decade after Dark Emu

Retrieved on: 
Wednesday, April 10, 2024

Bruce Pascoe is best known for his natural history, Dark Emu, which argues that systems of pre-colonial food production and land management in Australia have been dramatically understated.

Key Points: 
  • Bruce Pascoe is best known for his natural history, Dark Emu, which argues that systems of pre-colonial food production and land management in Australia have been dramatically understated.
  • At last count, the book had sold at least 360,000 copies of the original edition – and many more in the form of adaptations, translations, children’s and overseas editions.
  • Since the publication of Dark Emu in 2014, Pascoe has had to endure extraordinary public scrutiny, as well as vehement attacks on his personal and professional reputation.
  • In light of the last ten years, Black Duck: A Year at Yumburra is a healing and necessary book.
  • The farm is a deliberate project designed to test, extend and materialise some of the ideas put forward in Dark Emu.
  • The meaning of Yumburra, Pascoe tells us, is Black Duck, the “supreme spiritual being of Yuin country”.

Six seasons on the farm

  • Through more than 60 subtitled journal entries, accompanied by numerous photographs and sketches, Pascoe charts the activities of his days.
  • These include labouring chores on the farm, visits paid and received (both there and interstate), thoughts, visions and experiments with food and agriculture, and memories and reflections on relationships reaching far back into childhood.
  • Pascoe describes life on the farm as solitary at times, but also active.
  • Daily farm work includes clearing watercourses or fixing tools and machinery, and at these times his friendships with the nonhuman are forged in both subtle and overt ways.
  • Despite their vigilance, the Spur-winged Plover loses a lot of chicks to eagles and foxes […] Their calls are ever-present on the farm.
  • If the horses gallop, an eagle passes, a dingo wakes or a car arrives, you hear about it instantly.
  • You can’t make friend with Birran Durran Durran because everything is a threat in its opinion.
  • Despite their vigilance, the Spur-winged Plover loses a lot of chicks to eagles and foxes […] Their calls are ever-present on the farm.
  • There is a sense of time moving on through the seasons.
  • Yumburra, too, was affected by that event, leading one of the farm workers to rename a whole section of the farm “Apocalypse Valley” in the aftermath.
  • “The unbridled pleasure I used to take in the forest, waters and shores is now tinged with sadness and dread.”

A true storyteller

  • The author is respectfully light on detail on these matters, but the reader is left in no doubt about their deep importance to him.
  • Pascoe’s authorial style sometimes comes across as a touch too lackadaisical and larrikin-esque, drifting as if unmoored.
  • And yet, he’s a true storyteller – and no sooner have you hesitated, than he reels you in again, and has you marvelling with him at the grandchildren’s handstands and cartwheels on the paddle board on the river, or at the cunning of the dingo pair who’ve taken out a young Buru (kangaroo) by gripping him by the ears and drowning him.
  • I assume it was the same animal because she made a great point of making sure I was watching her expertise.
  • It might be a romantic thought or a wish for longevity of a friend but, whatever the case, I enjoy the personality.“
  • Sometimes Pascoe quotes from her journal entries, discrete and beautifully rendered observations of wildlife on her own nearby property.
  • But as I was reading, I found myself wondering how else Lyn contributed to the book, and on what terms.

Connection to culture and Country

  • For anyone with lingering doubts about Pascoe’s commitment and connection to Country, this book will set them straight.
  • It is a quiet, funny, warm and insistent call to return to and care for Country.


Julienne van Loon has been a recipient of funding from Creative Australia, Creative Victoria and ArtsWA.

Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024

Retrieved on: 
Tuesday, April 9, 2024

To register, click here .

Key Points: 
  • To register, click here .
  • The event will feature two key opinion leaders who will discuss the clinical symptoms and the natural history of oculopharyngeal muscular dystrophy (OPMD), a rare genetic muscle disorder.
  • The key opinion leaders will also review the clinical and radiographic methods employed to evaluate disease progression and discuss the current treatment landscape for patients diagnosed with OPMD.
  • A live question and answer session will follow the formal presentations.

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Retrieved on: 
Monday, April 8, 2024

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency (PXE, pseudoxanthoma elasticum) and ENPP1 Deficiency.

Key Points: 
  • “We are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • The patients were assigned to three dose cohorts of INZ-701: 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=4).
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.

Filippo Berio announces exclusive partnership with Alzheimer's Drug Discovery Foundation, supporting critical research and brain health

Retrieved on: 
Monday, April 8, 2024

LYNDHURST, N.J., April 8, 2024 /PRNewswire/ -- Filippo Berio, one of the nation's top-selling and longstanding olive oil brands, has established an exclusive partnership with the Alzheimer's Drug Discovery Foundation to raise awareness for Alzheimer's disease and contribute crucial funds to support groundbreaking research aimed at finding a cure for Alzheimer's and related dementias. The collaboration is a natural fit, given the growing body of research that indicates properties in olive oil may not only play a pivotal role in cardiovascular health but also provide important benefits to brain health. The partnership aims to increase overall awareness of lifestyle changes, including a healthy diet, that may positively affect brain health, which can help consumers to make healthier, informed choices.

Key Points: 
  • The collaboration is a natural fit, given the growing body of research that indicates properties in olive oil may not only play a pivotal role in cardiovascular health but also provide important benefits to brain health.
  • The partnership aims to increase overall awareness of lifestyle changes, including a healthy diet, that may positively affect brain health, which can help consumers to make healthier, informed choices.
  • Studies indicate that consuming olive oil may have protective effects on the brain and reduce the risk of Alzheimer's."
  • This will be the second consecutive year Filippo Berio is supporting one of the ADDF's signature fundraising events.

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Retrieved on: 
Wednesday, March 13, 2024

In December 2023, Clene reported new data from the ongoing open-label extension of the HEALEY ALS Platform Trial.

Key Points: 
  • In December 2023, Clene reported new data from the ongoing open-label extension of the HEALEY ALS Platform Trial.
  • Clene plans to submit additional data to the FDA to advance the CNM-Au8 accelerated approval discussions in 2024.
  • In December 2023, Clene announced the publication of a peer-reviewed article describing brain target engagement by CNM-Au8.
  • Clene expects that its resources as of December 31, 2023, will be sufficient to fund its operations into the fourth quarter of 2024.

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, March 12, 2024

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “We believe we are well-positioned to continue to advance INZ-701 through several anticipated value-creating milestones in the year ahead,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • Calciphylaxis represents a devastating condition characterized by pathologic mineralization and intimal proliferation.
  • Patients will receive 1.8 mg/kg of INZ-701 once weekly, coinciding with their hemodialysis treatment, for a total of 30 days.
  • The study’s primary endpoint will assess safety and change from baseline plasma PPi concentration, with secondary endpoints including PK and PD parameters.

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Retrieved on: 
Monday, March 25, 2024

Data from these studies showed clinically meaningful effects, including substantial and durable reductions in convulsive seizure frequency and improvements in multiple measures of cognition and behavior that support the potential for disease modification.

Key Points: 
  • Data from these studies showed clinically meaningful effects, including substantial and durable reductions in convulsive seizure frequency and improvements in multiple measures of cognition and behavior that support the potential for disease modification.
  • These improvements were observed among a highly refractory group of patients who were already taking the best available anti-seizure medicines.
  • Today, the Company also announced clearance from the U.S. Food and Drug Administration (FDA) that allows patients to receive three doses of 70mg followed by continued dosing at 45mg.
  • “STK-001 is the first medicine in development to demonstrate substantial and durable reductions in seizure frequency and improvements in multiple measures of cognition and behavior.

World-Renowned Ancient DNA Expert, HHMI Investigator, and MacArthur Award Winner Beth Shapiro, Ph.D., Joins Colossal as Chief Science Officer

Retrieved on: 
Tuesday, March 19, 2024

Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.

Key Points: 
  • Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.
  • In this role, she will oversee the continued expansion of the company’s de-extinction and conservation science teams.
  • A MacArthur “Genius Grant” Award winner and National Geographic Explorer, Beth Shapiro is a pioneer in the scientific fields of ancient DNA and paleogenomics.
  • “She’s the author of inspiring books 'How to Clone a Mammoth' and 'Life as We Made It,' plus an HHMI and MacArthur Fellow.